Percheron Therapeutics (AU:PER) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Percheron Therapeutics Limited announced the results of its Annual General Meeting, where all resolutions were decided by a poll. Notably, the adoption of the Remuneration Report was met with more than 25% opposition, marking a first strike under Australian corporate law. The company continues to focus on its lead therapy for Duchenne Muscular Dystrophy, with new trial data expected soon.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.
